npj Breast Cancer

Article	Citations
Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer	301
Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies	178
HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now	123
Triple negative breast cancer: Pitfalls and progress	122
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group	110
Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer	103
Evolution of HER2-low expression from primary to recurrent breast cancer	94
Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group	92
Immunotherapy in breast cancer: an overview of current strategies and perspectives	71
Immunotherapy for early triple negative breast cancer: research agenda for the next decade	68
Connected-UNets: a deep learning architecture for breast mass segmentation	63
ARe we there yet? Understanding androgen receptor signaling in breast cancer	58
Interaction between CD36 and FABP4 modulates adipocyte-induced fatty acid import and metabolism in breast cancer	52
Large language model (ChatGPT) as a support tool for breast tumor board	48
HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment	48
Upregulation of lipid metabolism genes in the breast prior to cancer diagnosis	46
Impact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant/adjuvant chemotherapy	45
PARP inhibition in breast cancer: progress made and future hopes	43
Circulating tRNA-derived small RNAs (tsRNAs) signature for the diagnosis and prognosis of breast cancer	42
Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer	40
Evidence-based guidelines for managing patients with primary ER+ HER2− breast cancer deferred from surgery due to the COVID-19 pandemic	40
The impact of lymphedema on health-related quality of life up to 10 years after breast cancer treatment	39
The acute effects of adjuvant radiation and chemotherapy on peripheral blood epigenetic age in early stage breast cancer patients	38
Poor response to neoadjuvant chemotherapy in metaplastic breast carcinoma	37
Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer	34

Breast cancer dormancy: need for clinically relevant models to address current gaps in knowledge	34
Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer	33
Dynamic contrast-enhanced breast MRI features correlate with invasive breast cancer angiogenesis	33
Tetrathiomolybdate (TM)-associated copper depletion influences collagen remodeling and immune response in the pre-metastatic niche of breast cancer	32
Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohort	32
Predicting breast cancer response to neoadjuvant treatment using multi-feature MRI: results from the I-SPY 2 TRIAL	32
Multimodal liquid biopsy for early monitoring and outcome prediction of chemotherapy in metastatic breast cancer	31
Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups	31
Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors	31
Overweight and prognosis in triple-negative breast cancer patients: a systematic review and meta-analysis	30
Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer	30
Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer	30
A perspective on the development and lack of interchangeability of the breast cancer intrinsic subtypes	29
Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis	29
The genomic landscape of metastatic histologic special types of invasive breast cancer	28
IL-1B drives opposing responses in primary tumours and bone metastases; harnessing combination therapies to improve outcome in breast cancer	28
Contrasting DCIS and invasive breast cancer by subtype suggests basal-like DCIS as distinct lesions	28
Long-term anti-inflammatory diet in relation to improved breast cancer prognosis: a prospective cohort study	27
Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (“METRIC”): a randomized multicenter study	27
Cyclin E expression is associated with high levels of replication stress in triple-negative breast cancer	27
A careful reassessment of anthracycline use in curable breast cancer	27
Clinical utility of genomic signatures in young breast cancer patients: a systematic review	27
Collagen fiber orientation disorder from H&E images is prognostic for early stage breast cancer: clinical trial validation	26
Prognostic implications of the expression levels of different immunoglobulin heavy chain-encoding RNAs in early breast cancer	26
Validation and real-world clinical application of an artificial intelligence algorithm for breast cancer detection in biopsies	25
Immunostimulatory and anti-tumor metronomic cyclophosphamide regimens assessed in primary orthotopic and metastatic murine breast cancer	25
Prognostic significance of residual nodal disease after neoadjuvant endocrine therapy for hormone receptor-positive breast cancer	25
Potential of ultra-high-resolution photon-counting CT of bone metastases: initial experiences in breast cancer patients	24
Pleomorphic adenomas and mucoepidermoid carcinomas of the breast are underpinned by fusion genes	24
Characterization of weaning-induced breast involution in women: implications for young women’s breast cancer	24
Allostatic load: a framework to understand breast cancer outcomes in Black women	23
Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence risk	23
A randomized intervention involving family to improve communication in breast cancer care	22
The clinical and molecular significance associated with STING signaling in breast cancer	22
Impact of low versus negative estrogen/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2-negative breast cancer	22
Retinoblastoma protein expression and its predictors in triple-negative breast cancer	22
Breast Cancer Consensus Subtypes: A system for subtyping breast cancer tumors based on gene expression	21
An emerging generation of endocrine therapies in breast cancer: a clinical perspective	21
The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data	21
Oncogene-mediated metabolic gene signature predicts breast cancer outcome	21
Subclonal heterogeneity and evolution in breast cancer	21
Deep learning models for histologic grading of breast cancer and association with disease prognosis	20
RNA sequencing-based single sample predictors of molecular subtype and risk of recurrence for clinical assessment of early-stage breast cancer	20
Prevalence of disease-causing genes in Japanese patients with BRCA1/2-wildtype hereditary breast and ovarian cancer syndrome	20
Integrative multiomics-histopathology analysis for breast cancer classification	20
Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study	20
Effects of systemic inflammation on relapse in early breast cancer	20
Association between the histopathological growth patterns of liver metastases and survival after hepatic surgery in breast cancer patients	20
Mechanism of action biomarkers predicting response to AKT inhibition in the I-SPY 2 breast cancer trial	19
MicroRNA-200c restoration reveals a cytokine profile to enhance M1 macrophage polarization in breast cancer	19

How can artificial intelligence models assist PD-L1 expression scoring in breast cancer: results of multi-institutional ring studies	19
Treatment scheduling effects on the evolution of drug resistance in heterogeneous cancer cell populations	19
FAK inhibition alone or in combination with adjuvant therapies reduces cancer stem cell activity	19
Using whole-genome sequencing data to derive the homologous recombination deficiency scores	19
Long non-coding RNA MIR200CHG promotes breast cancer proliferation, invasion, and drug resistance by interacting with and stabilizing YB-1	19
Histopathologic, immunophenotypic, and proteomics characteristics of low-grade phyllodes tumor and fibroadenoma: more similarities than differences	19
Sulforaphane suppresses metastasis of triple-negative breast cancer cells by targeting the RAF/MEK/ERK pathway	18
Spatial distribution of B cells and lymphocyte clusters as a predictor of triple-negative breast cancer outcome	17
A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer	17
Skeletal muscle reprogramming by breast cancer regardless of treatment history or tumor molecular subtype	17
PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy	17
Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer	17
The human intermediate prolactin receptor is a mammary proto-oncogene	17
Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE	17
Brain radiotherapy, tremelimumab-mediated CTLA-4-directed blockade +/− trastuzumab in patients with breast cancer brain metastases	17
Ivermectin converts cold tumors hot and synergizes with immune checkpoint blockade for treatment of breast cancer	17
Comprehensive characterization of distinct genetic alterations in metastatic breast cancer across various metastatic sites	16
Unmasking the immune microecology of ductal carcinoma in situ with deep learning	16
Effect of metformin versus placebo on metabolic factors in the MA.32 randomized breast cancer trial	16
Whole-exome sequencing identifies somatic mutations and intratumor heterogeneity in inflammatory breast cancer	16
MRI to assess response after neoadjuvant chemotherapy in breast cancer subtypes: a systematic review and meta-analysis	16
Circulating tumor cell number and endocrine therapy index in ER positive metastatic breast cancer patients	16
Oncogenic action of the exosome cofactor RBM7 by stabilization of CDK1 mRNA in breast cancer	16
TERT promoter hotspot mutations and gene amplification in metaplastic breast cancer	16
Effectiveness of the Korean National Cancer Screening Program in reducing breast cancer mortality	16
Cisplatin +/− rucaparib after preoperative chemotherapy in patients with triple-negative or BRCA mutated breast cancer	16
Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer	15
HBXIP induces anoikis resistance by forming a reciprocal feedback loop with Nrf2 to maintain redox homeostasis and stabilize Prdx1 in breast cancer	15
De-escalation in breast cancer surgery	15
Circulating amino acids and amino acid-related metabolites and risk of breast cancer among predominantly premenopausal women	15
Meta-analyses of visceral versus non-visceral metastatic hormone receptor-positive breast cancer treated by endocrine monotherapies	15
Circulating cell-free DNA-based methylation patterns for breast cancer diagnosis	15
Automated percent mammographic density, mammographic texture variation, and risk of breast cancer: a nested case-control study	15
Inflammatory cytokines and distant recurrence in HER2-negative early breast cancer	14
Plasma extracellular vesicle long RNA profiles in the diagnosis and prediction of treatment response for breast cancer	14
Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials	14
Genetic epidemiology of BRCA1- and BRCA2-associated cancer across Latin America	14
Concomitant analyses of intratumoral microbiota and genomic features reveal distinct racial differences in breast cancer	14
Efficacy of platinum-based chemotherapy in metastatic breast cancer and HRD biomarkers: utility of exome sequencing	14
GRHL2 motif is associated with intratumor heterogeneity of cis-regulatory elements in luminal breast cancer	14
Unique cellular protrusions mediate breast cancer cell migration by tethering to osteogenic cells	14
Tocilizumab overcomes chemotherapy resistance in mesenchymal stem-like breast cancer by negating autocrine IL-1A induction of IL-6	14
Clinical behavior and outcomes of breast cancer in young women with germline BRCA pathogenic variants	14
Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness	13
Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer	13
Olaparib for metastatic breast cancer in a patient with a germline PALB2 variant	13
Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy	13
RIPK1 is a negative mediator in Aquaporin 1-driven triple-negative breast carcinoma progression and metastasis	13
Abemaciclib in combination with pembrolizumab for HR+, HER2− metastatic breast cancer: Phase 1b study	13
Crown-like structures in breast adipose tissue of breast cancer patients: associations with CD68 expression, obesity, metabolic factors and prognosis	13
High GPER expression in triple-negative breast cancer is linked to pro-metastatic pathways and predicts poor patient outcomes	13
FOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 036	12
Accuracy of breast MRI in evaluating nodal status after neoadjuvant therapy in invasive lobular carcinoma	12
Characterization of four subtypes in morphologically normal tissue excised proximal and distal to breast cancer	12
Association of treatment-emergent symptoms identified by patient-reported outcomes with adjuvant endocrine therapy discontinuation	12
Ancestry-associated transcriptomic profiles of breast cancer in patients of African, Arab, and European ancestry	12
Development and pilot of an online, personalized risk assessment tool for a breast cancer precision medicine trial	12
ctDNA and residual cancer burden are prognostic in triple-negative breast cancer patients with residual disease	12
Comprehensive characterization of pre- and post-treatment samples of breast cancer reveal potential mechanisms of chemotherapy resistance	12
Breast adipocyte size associates with ipsilateral invasive breast cancer risk after ductal carcinoma in situ	12
Lymphovascular invasion, race, and the 21-gene recurrence score in early estrogen receptor-positive breast cancer	12
Preoperative magnetic resonance imaging use and oncologic outcomes in premenopausal breast cancer patients	11
Fibroblast growth factor receptor facilitates recurrence of minimal residual disease following trastuzumab emtansine therapy	11
Endoplasmic reticulum stress inhibits AR expression via the PERK/eIF2α/ATF4 pathway in luminal androgen receptor triple-negative breast cancer and prostate cancer	11
Hyperleptinemia in obese state renders luminal breast cancers refractory to tamoxifen by coordinating a crosstalk between Med1, miR205 and ErbB	11
Treatment-related amenorrhea in a modern, prospective cohort study of young women with breast cancer	11
Sensory nerves enhance triple-negative breast cancer invasion and metastasis via the axon guidance molecule PlexinB3	11
Targeting nucleotide metabolism enhances the efficacy of anthracyclines and anti-metabolites in triple-negative breast cancer	11
Population-based estimates of breast cancer risk for carriers of pathogenic variants identified by gene-panel testing	11
Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan	11
Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer	11
Predicting breast cancer types on and beyond molecular level in a multi-modal fashion	11
Disease characterization in liquid biopsy from HER2-mutated, non-amplified metastatic breast cancer patients treated with neratinib	11
Epigenome erosion and SOX10 drive neural crest phenotypic mimicry in triple-negative breast cancer	11
Co-dependency for MET and FGFR1 in basal triple-negative breast cancers	11
Integration of clinical features and deep learning on pathology for the prediction of breast cancer recurrence assays and risk of recurrence	11
The breast pre-cancer atlas illustrates the molecular and micro-environmental diversity of ductal carcinoma in situ	11
Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial	10
Trigger point injection for post-mastectomy pain: a simple intervention with high rate of long-term relief	10
Interim clinical trial analysis of intraoperative mass spectrometry for breast cancer surgery	10

The 21-gene recurrence score in early non-ductal breast cancer: a National Cancer Database analysis	10
Somatic genetic aberrations in benign breast disease and the risk of subsequent breast cancer	10
High prevalence of APOA1/C3/A4/A5 alterations in luminal breast cancers among young women in East Asia	10
Anti-tumor effects of an ID antagonist with no observed acquired resistance	10
Adolescent alcohol, nuts, and fiber: combined effects on benign breast disease risk in young women	10
Mutual exclusivity of ESR1 and TP53 mutations in endocrine resistant metastatic breast cancer	10
Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition	10
Development and validation for research assessment of Oncotype DX® Breast Recurrence Score, EndoPredict® and Prosigna®	10
Incidence and impact of brain metastasis in patients with hereditary BRCA1 or BRCA2 mutated invasive breast cancer	10
Investigation of monogenic causes of familial breast cancer: data from the BEACCON case-control study	10
Ductal carcinoma in situ: a risk prediction model for the underestimation of invasive breast cancer	10
Alternative trastuzumab dosing strategies in HER2-positive early breast cancer are associated with patient out-of-pocket savings	10
Phase I study of A166, an antibody‒drug conjugate in advanced HER2-expressing solid tumours	10
Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer	10
Systematic evaluation of scoring methods for Ki67 as a surrogate for 21-gene recurrence score	10
Clinical outcomes of de novo metastatic HER2-low breast cancer: a National Cancer Database Analysis	10
Risk of primary lung cancer after adjuvant radiotherapy in breast cancer—a large population-based study	10
Estrogen receptor beta repurposes EZH2 to suppress oncogenic NFκB/p65 signaling in triple negative breast cancer	10
Evaluation of disseminated tumor cells and circulating tumor cells in patients with breast cancer receiving adjuvant zoledronic acid	10
The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer	10
Breast cancer dormancy is associated with a 4NG1 state and not senescence	10
Estrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancer	10
Acupuncture versus cognitive behavioral therapy for pain among cancer survivors with insomnia: an exploratory analysis of a randomized clinical trial	10
Association between the nucleosome footprint of plasma DNA and neoadjuvant chemotherapy response for breast cancer	10
Ethnic and biological differences in the association between physical activity and survival after breast cancer	10
Changes in intestinal microbiota in postmenopausal oestrogen receptor-positive breast cancer patients treated with (neo)adjuvant chemotherapy	10
Body fatness and mTOR pathway activation of breast cancer in the Women’s Circle of Health Study	9
Primary endocrine resistance of ER+ breast cancer with ESR1 mutations interrogated by droplet digital PCR	9
Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab	9
A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013	9
Contralateral breast cancer risk in patients with ductal carcinoma in situ and invasive breast cancer	9
The impact of age and nodal status on variations in oncotype DX testing and adjuvant treatment	9
Clinical-pathologic characteristics and response to neoadjuvant chemotherapy in triple-negative low Ki-67 proliferation (TNLP) breast cancers	9
FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer	9
Germline RAD51B variants confer susceptibility to breast and ovarian cancers deficient in homologous recombination	9
STING agonism enhances anti-tumor immune responses and therapeutic efficacy of PARP inhibition in BRCA-associated breast cancer	9
C/EBPβ isoform-specific regulation of migration and invasion in triple-negative breast cancer cells	9
Do current family history-based genetic testing guidelines contribute to breast cancer health inequities?	9
DAXX-inducing phytoestrogens inhibit ER+ tumor initiating cells and delay tumor development	9
Multianalyte liquid biopsy to aid the diagnostic workup of breast cancer	9
Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer	9
Survival benefit of platinum-based regimen in early stage triple negative breast cancer: A meta-analysis of randomized controlled trials	9
Enhanced immune response outperform aggressive cancer biology and is associated with better survival in triple-negative breast cancer	9
Gene signatures in patients with early breast cancer and relapse despite pathologic complete response	9
Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and/or leptomeningeal disease (ROSET-BM)	9
Tissue-agnostic drug approvals: how does this apply to patients with breast cancer?	9
Systemic immune reaction in axillary lymph nodes adds to tumor-infiltrating lymphocytes in triple-negative breast cancer prognostication	9
PIK3CA co-occurring mutations and copy-number gain in hormone receptor positive and HER2 negative breast cancer	9
High CYP27A1 expression is a biomarker of favorable prognosis in premenopausal patients with estrogen receptor positive primary breast cancer	9
Interrogating breast cancer heterogeneity using single and pooled circulating tumor cell analysis	8
Tumor immune microenvironment of self-identified African American and non-African American triple negative breast cancer	8
High prevalence of somatic PIK3CA and TP53 pathogenic variants in the normal mammary gland tissue of sporadic breast cancer patients revealed by duplex sequencing	8
Inherited predisposition to breast cancer in the Carolina Breast Cancer Study	8
Evaluation of the association of heterozygous germline variants in NTHL1 with breast cancer predisposition: an international multi-center study of 47,180 subjects	8
Mechanostimulation of breast myoepithelial cells induces functional changes associated with DCIS progression to invasion	8
Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled	8
Prediction of quality of life in early breast cancer upon completion of adjuvant chemotherapy	8
Ductal keratin 15+ luminal progenitors in normal breast exhibit a basal-like breast cancer transcriptomic signature	8
Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer	8
Integrating single-cell RNA-sequencing and functional assays to decipher mammary cell states and lineage hierarchies	8
Identifying breast cancer patients at risk of relapse despite pathological complete response after neoadjuvant therapy	8
Stem-like breast cancer cells in the activated state resist genetic stress via TGFBI-ZEB1	8
Untangling the clinicopathological significance of MRE11-RAD50-NBS1 complex in sporadic breast cancers	8
MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit	8
Recurrence biomarkers of triple negative breast cancer treated with neoadjuvant chemotherapy and anti-EGFR antibodies	8
UACA locus is associated with breast cancer chemoresistance and survival	7
The LINC01119-SOCS5 axis as a critical theranostic in triple-negative breast cancer	7
Predicting neoadjuvant chemotherapy benefit using deep learning from stromal histology in breast cancer	7
Crystal structure of active CDK4-cyclin D and mechanistic basis for abemaciclib efficacy	7
Is conservative management of ductal carcinoma in situ risky?	7
Biological insights and novel biomarker discovery through deep learning approaches in breast cancer histopathology	7
Evaluation of overall survival and barriers to surgery for patients with breast cancer treated without surgery: a National Cancer Database analysis	7
Immune landscape of breast tumors with low and intermediate estrogen receptor expression	7
Genetic interactions among Brca1, Brca2, Palb2, and Trp53 in mammary tumor development	7
Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors	7
The incidence of discordant clinical and genomic risk in patients with invasive lobular or ductal carcinoma of the breast: a National Cancer Database Study	7
Apatinib plus vinorelbine versus vinorelbine for metastatic triple-negative breast cancer who failed first/second-line treatment: the NAN trial	7
A phase II trial of an alternative schedule of palbociclib and embedded serum TK1 analysis	7
S-nitrosylated and non-nitrosylated COX2 have differential expression and distinct subcellular localization in normal and breast cancer tissue	7
SOX4 and SMARCA4 cooperatively regulate PI3k signaling through transcriptional activation of TGFBR2	7
Cellphone enabled point-of-care assessment of breast tumor cytology and molecular HER2 expression from fine-needle aspirates	7
Novel evolutionary dynamics of small populations in breast cancer adjuvant and neoadjuvant therapy	7
The cytosolic iron–sulfur cluster assembly (CIA) pathway is required for replication stress tolerance of cancer cells to Chk1 and ATR inhibitors	6
Adaptive stress response genes associated with breast cancer subtypes and survival outcomes reveal race-related differences	6
The different prognostic significance of polysialic acid and CD56 expression in tumor cells and lymphocytes identified in breast cancer	6
Polygenic risk score for the prediction of breast cancer is related to lesser terminal duct lobular unit involution of the breast	6
Characterisation of PALB2 tumours through whole-exome and whole-transcriptomic analyses	6
Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer	6
Automated and rapid detection of cancer in suspicious axillary lymph nodes in patients with breast cancer	6
Solid-basaloid variant of adenoid cystic carcinoma of the breast with near complete response to neoadjuvant chemotherapy	6
Automated quantification of levels of breast terminal duct lobular (TDLU) involution using deep learning	6
Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer models	6
Bone mineral density in women newly diagnosed with breast cancer: a prospective cohort study	6
PAM50 subtyping and ROR score add long-term prognostic information in premenopausal breast cancer patients	6
Heparanase: a potential marker of worse prognosis in estrogen receptor-positive breast cancer	6